Skip to main content
Click here to get access to our Free Course on Momentum Investing Strategy

NSE · GUFICBIO

GUFIC BIO SC

HealthcarePharmaceuticals & Biotechnology₹4253 cr market cap
₹431.90 ▲ +2.29% today As of 19 Nov 2026
52-week low ₹273.5052-week high ₹487.00

-13.3% from the 52-week high · +54.4% above the low

Gufic Biosciences Ltd. engages in the manufacture and marketing of active pharmaceutical ingredients, generic pharmaceuticals, and related services. The company is headquartered in Mumbai, Maharashtra and currently employs 1,382 full-time employees. The company went IPO on 2004-10-19. The firm operates through the Pharmaceutical segment. The company has pharmaceutical products under categories, such as Criti Care, including Doxific, Micafung, Rabol and Tigefic-Plus; Criticare Life, including Ticofic-200 and Gufivan-500; Ferticare, including Puregraf 75IU 3D, Cetrocare 0.25mg 3D and Follicare 150IU 3D; Spark, including Aznee Duo, Eclin, Flabone, Vipro M and Zad G; Herbal, including Bocomo-Forte, Sallaki-Liniment, Zulcer Cap and Smashit tablet, and Aesthaderm, including Prosil, Moiseta Face Wash and Revanox Serum. Its personal care products include StretchNil, Shapers-Natural Feel, Shaper-DryFeel and RollOn. Its products under active pharmaceutical ingredient (API)/bulk drugs include Micafungin, Anidulafungin, Sulconazole and Everolimus. Its Gufic Stridden includes Irvical and Eve.

The short version. GUFIC BIO SC reported revenue of ₹288 crore for Sep 2026, up 21.5% from a year earlier. Net profit was ₹23 crore (up 35.3% year on year). Return on equity was 9.7% in Mar 2026. Promoter holding was 72.5% in Sep 2026, down 0.01 points over 8 quarters.

1 · The price

How has the stock traded?

GUFIC BIO SC trades 13.3% below its 52-week high and 54.4% above its 52-week low.

Change over period: —

1M+4.4%
3M+0.1%
6M+47.8%
1Y+28.2%

2 · The business

Is it growing?

Sales, year on year+21.5%

Sep 2026 revenue of ₹288 cr.

Profit, year on year+35.3%

Sep 2026 net profit of ₹23 cr.

Net margin8.1%

1.0 pts higher than a year earlier.

Reported results · ₹ crore

Revenue and profit

Show the numbers

Quarterly

Sep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue288261252231237224205208
Net profit232222121713819
Net margin %8.18.68.75.47.15.83.89.3
EPS (₹)2.342.222.181.241.681.30.771.93

Annual

FY2026FY2025FY2024
Revenue944820807
Net profit647086
Net margin %6.88.510.7
EPS (₹)6.46.958.59

3 · The quality

How well does it turn capital into profit?

Return on equity was 9.7% in Mar 2026; debt to equity is 0.58.

Profitability · 4 years

Returns and margins

Mar 2026Mar 2025Mar 2024Mar 2023
Return on equity %9.711.616.2—
Return on capital %14.915.018.2—
EBITDA margin %16.316.818.3—
Net margin %6.88.510.7—

Compound growth

Revenue vs profit

3 years5 years
Revenue CAGR——
Profit CAGR——
Debt to equity0.58
Interest cover3.4x
Current ratio1.55
P/E ratio57.1

4 · The owners

Who holds it, and are they adding?

Promoter holding72.5%

Down 0.01 pts over 8 quarters.

Foreign institutions0.45%

Up 0.15 pts over 8 quarters.

Domestic institutions3.38%

Up 0.4 pts over 8 quarters.

Mutual fund schemes14

+2 versus the previous month.

Shareholding pattern (%)

Quarter by quarter

Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026Change
Promoter72.5172.5172.5172.572.572.572.572.5-0.01
FII0.30.310.320.340.440.420.460.45+0.15
DII2.983.393.383.653.743.833.683.38+0.4
Public24.223.7923.823.5123.3223.2423.3623.67-0.53

Mutual fund holdings · Oct 2026

14 schemes hold this stock

12 the month before.

  • Bank of India Business Cycle Fund1.46% of NAV
  • ICICI Prudential Life Cycle Fund 20311.4% of NAV
  • Bank Of India MID CAP TAX FUND Series 2 ( A 10 year Close -ended equity linked savings scheme)1.07% of NAV
  • Bank Of India Manufacturing and Infrastructure Fund1.05% of NAV
  • Bank Of India SMALL CAP FUND0.64% of NAV
  • ICICI Prudential Quality Fund0.49% of NAV
  • ICICI Prudential Multi Cap Fund0.34% of NAV
  • SBI Healthcare Opportunities Fund0.27% of NAV

See what mutual funds are buying

5 · The model view

What does our factor model say?

Factor scores, model flags and screen results for GUFIC BIO SC are part of the Wright portfolio review.

Run your free portfolio review

Watchouts

What to review

Model flags are shown inside the portfolio review, alongside your other holdings.

Model ratingLocked
Factor betaLocked
VolatilityLocked

Quick answers

Common questions about GUFIC BIO SC

What is the GUFIC BIO SC share price?

GUFIC BIO SC (GUFICBIO) last closed at ₹431.90, up 2.29% on the day. Its 52-week range is ₹273.50 to ₹487.00.

What is the market cap of GUFIC BIO SC?

GUFIC BIO SC has a market capitalisation of about ₹4,253 crore. Its price-to-earnings ratio is 57.1.

How are GUFIC BIO SC's latest results?

GUFIC BIO SC reported revenue of ₹288 crore for Sep 2026, up 21.5% from a year earlier. Net profit was ₹23 crore (up 35.3% year on year). Return on equity was 9.7% in Mar 2026. Promoter holding was 72.5% in Sep 2026, down 0.01 points over 8 quarters.

Who owns GUFIC BIO SC?

As of Sep 2026, shareholding was: Promoter 72.5%, FII 0.45%, DII 3.38%, Public 23.67%.

How many mutual funds hold GUFIC BIO SC?

14 mutual fund schemes held GUFIC BIO SC in October 2026. That compares with 12 the month before.

Corporate actions

Recent dividends, bonuses and splits

  • 22 Sep 2025 · Final Dividend - Rs. 0.1
  • 17 Sep 2024 · Final Dividend - Rs. 0.1
  • 21 Sep 2023 · Final Dividend - Rs. 0.1
  • 24 Aug 2022 · Final Dividend - Rs. 0.1
  • 09 Sep 2021 · Final Dividend - Rs. 0.1
  • 03 Nov 2020 · Final Dividend - Rs. 0.05

Financials are as reported by the company (consolidated), in ₹ crore. Source: FinEdge exchange filings feed. Figures can differ from other sites because of one-off items and restatements. Callouts above are arithmetic on reported data, not recommendations.

Research data on this page is provided under Wright Research's SEBI Research Analyst registration. The Terms & Conditions of our Research Analyst services apply.